About BioRay Pharmaceutical
BioRay Pharmaceutical is a Healthcare company based in Taizhou (China) founded in 2019, and was acquired by PAG in September 2019. It operates as an antibody therapeutics for immunology and oncology are developed. BioRay Pharmaceutical has raised $214.97 million across 1 funding round from investors including PAG. The company has 47 employees. BioRay Pharmaceutical was last valued at $1.9 billion in January 2023. Its chief executive is Haibin Wang. Its focus areas include Life Sciences, Immunology, Drugs and Autoimmune Diseases. Its legal entity is BIORAY PHARMACEUTICAL CORP. Its competitors include Moderna, BeiGene, Incyte, Horizon Therapeutics and Forge Biologics and 4 more; 7 of its 9 listed competitors have raised funding.
Company details
BioRay Pharmaceutical was founded in 2019 in Taizhou, China, within the biotechnology sector. Therapeutics are developed using an antibody-technology platform targeted at immune-mediated diseases, including rheumatoid arthritis, psoriasis, and Ankylosing Spondylitis. Drugs for cancer and tumors are also offered. Formulated products derived from organic ingredients are provided to support health restoration and bodily balance. Operations focus on immunology and oncology research and development.
- Headquarters Taizhou, China
- Employees 47
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website bioraypharm.com
- Social LinkedIn
- Acquired by PAG (Sep 2019)
- Legal Name Bioray Pharmaceutical Corp
Funding Insights of BioRay Pharmaceutical
BioRay Pharmaceutical has successfully raised a total of $214.97M through 1 strategic funding round. The most recent funding activity was a Series D round of $214.97 million completed in December 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $214.97M
- Total Rounds 1
- Last Round Series D — $214.97M
- First Round $214.97M
(Dec 2022)
- Investors Count 1
All 1 funding rounds of BioRay Pharmaceutical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2022 | $214.97M | Series D | $1.9B | – | – |
| Date | Valuation | Stage |
|---|---|---|
| Dec 2022 | $1.9B | •••••••• |
Full valuation and stage history of BioRay Pharmaceutical
Every valuation point, the growth-stage changes (minicorn, soonicorn, unicorn) and the dates behind them require an active premium plan.
- All valuation points
- Stage changes
- Dates
- Exports
Verified entity values are shown only after access is granted.
Last known valuation $1.9B (Jan 2023). 1 investors in total: 1 institutional.
Investors in BioRay Pharmaceutical
BioRay Pharmaceutical has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include PAG.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Alternative investment firm | – | pag.com | - |
Investor details for BioRay Pharmaceutical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of BioRay Pharmaceutical
4 people are tracked at BioRay Pharmaceutical (3 in leadership, 1 in team); the tracked headcount is 47.
| Name | Role | Group |
|---|---|---|
Haibin Wang | CEO | Leadership |
Yuntao Wan | Vice President Clinical Research | Leadership |
Jie Zhu | Associate Director Of Cell Biology | Leadership |
Zhenwu Luo | Senior Scientist | Team |
Complete people profiles for BioRay Pharmaceutical
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of BioRay Pharmaceutical
4 dated milestones of BioRay Pharmaceutical across 3 years, from founding to its latest funding, stage changes and deals.
- Founded BioRay Pharmaceutical is founded.
- Exit Acquired by PAG.
- Funding First funding round of $215.0M.
- Milestone Reaches Unicorn status.
Competitors of BioRay Pharmaceutical
BioRay Pharmaceutical has 9 listed competitors in our database, 7 of them funded. They include Moderna, BeiGene, Incyte, Horizon Therapeutics and Forge Biologics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | – | 1,387 | Small molecules are developed for cancer and skin disease treatments. | |
| horizontherapeutics.com | 2008 | Dublin, Ireland | $61.78M | – | Developer of drugs for treating rare and autoimmune diseases | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| morphosys.com | 1992 | Planegg, Germany | – | 732 | Therapeutic antibodies for cancer and other diseases are developed. | |
| argenx.com | 2008 | Ghent, Belgium | $61.9M | 355 | Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| alxoncology.com | 2015 | Burlingame, United States | $123.02M | 59 | ALX Oncology is focused on advancing cancer treatment therapies. |
Detailed competitors of BioRay Pharmaceutical
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of BioRay Pharmaceutical
The website of BioRay Pharmaceutical (bioraypharm.com) receives about 2K visits a month.
- Monthly visits2K
▲ 421.9% vs previous month
Top companies in Immunology & Cancer Therapeutics
10 companies that operate in the same segment as BioRay Pharmaceutical (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 213.52 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bioray Pharmaceutical
Complete news archive for BioRay Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about BioRay Pharmaceutical
BioRay Pharmaceutical was founded in 2019 and raised its 1st funding round 3 years after it was founded.
BioRay Pharmaceutical is headquartered in Taizhou, China. It is registered at Taizhou, Jiangsu, China.
Haibin Wang is the current CEO of BioRay Pharmaceutical.
BioRay Pharmaceutical is a funded company, having raised a total of $214.97M across 1 funding round to date. The company's 1st funding round was a Series D of $214.97M, raised on Dec 2022.
BioRay Pharmaceutical has 47 employees.
BioRay Pharmaceutical was founded in 2019 in Taizhou, China, within the biotechnology sector. Therapeutics are developed using an antibody-technology platform targeted at immune-mediated diseases, including rheumatoid arthritis, psoriasis, and Ankylosing Spondylitis. Drugs for cancer and tumors are also offered. Formulated products derived from organic ingredients are provided to support health restoration and bodily balance. Operations focus on immunology and oncology research and development.
BioRay Pharmaceutical has 1 investor. Key investors include PAG.
The valuation of BioRay Pharmaceutical is $1.9B as of Jan 2023.
BioRay Pharmaceutical operates through Bioray Pharmaceutical Corp.
Yes. BioRay Pharmaceutical was acquired by PAG in September 2019.